Phase II Trial Snapshot: AXN-201

Northlake Research Network - Data cut: 2025-11-30

Protocol overview

AXN-201 is a fictional oral anti-inflammatory candidate evaluated in adults with moderate plaque psoriasis. This snapshot is a simulated example designed for document-parsing tests (no real clinical claims).

Design

• Randomized, double-blind, placebo-controlled; 1:1:1 allocation.
• Arms: Placebo, AXN-201 50 mg QD, AXN-201 100 mg QD for 12 weeks.
• Primary endpoint: PASI-75 response at Week 12.
• Key safety endpoints: treatment-emergent adverse events (TEAEs), labs, and vitals.

Enrollment summary

Site	Country	Screened	Randomized	Completed W12	Discontinued
NLK-101	US	74	60	56	4
NLK-102	US	61	48	45	3
NLK-201	CA	52	40	37	3
NLK-301	UK	58	45	41	4
NLK-401	DE	49	39	36	3
Total	-	294	232	215	17

Interpretation note

All values are fabricated for illustration and do not reflect any real study.

Efficacy and safety (simulated)

Summary of Week 12 efficacy and common TEAEs.

Measure	Placebo (n=77)	50 mg (n=78)	100 mg (n=77)
PASI-75 responders	18 (23.4%)	32 (41.0%)	39 (50.6%)
Mean change in PASI	-3.8	-6.1	-7.0
DLQI improvement (pts)	+2.1	+4.0	+4.6

Common TEAE (>=5%)	Placebo	50 mg	100 mg
Headache	6.5%	7.7%	9.1%
Nausea	3.9%	6.4%	7.8%
Upper respiratory symptoms	9.1%	10.3%	11.7%
ALT elevation (mild)	1.3%	2.6%	5.2%

Safety monitoring actions

- Repeat hepatic panel within 7 days for any ALT >= 2x ULN.
- Hold dosing if ALT >= 5x ULN or if symptoms suggest hepatitis.
- Escalate to medical monitor within 24 hours for serious adverse events.

Vector plot: subject-level lab trend

Example vector chart plotting ALT (U/L) vs. study day for selected subjects.



Point list (for parsing tests)

Subject	Day	ALT (U/L)
S-014	0	22.8
S-014	14	24.1
S-014	28	25.5
S-014	56	32.3
S-014	84	32.0
S-033	0	24.5
S-033	14	25.3
S-033	28	29.0
S-033	56	28.0
S-033	84	43.9
S-058	0	28.5
S-058	14	28.1

Coordinates on the plot are derived from the raw values above and rendered as vector circles and polylines.